| Autor: |
Etienne H; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland., Battilana B; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland., Spicer J; Department of Surgery, McGill University Health Center, Montreal, Québec, Canada., Werner RS; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland., Opitz I; Department of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland. |
| Jazyk: |
angličtina |
| Zdroj: |
JTCVS open [JTCVS Open] 2024 Mar 29; Vol. 19, pp. 338-346. Date of Electronic Publication: 2024 Mar 29 (Print Publication: 2024). |
| DOI: |
10.1016/j.xjon.2024.03.012 |
| Abstrakt: |
Competing Interests: Dr Opitz reports the following disclosures: Roche (institutional grant for fellowship and speakers bureau), Roche Genentech (steering committee), AstraZeneca (advisory board and speakers bureau, steering committee), Medtronic (institutional grant and advisory board), MSD (advisory board), BMS (advisory board), and Intuitive (proctorship). Dr Spicer reports the following disclosures: AstraZeneca (advisory board, speakers bureau, grant to institution, clinical trial leadership), Merck (advisory board, speakers bureau, grant to institution, clinical trial leadership), BMS (advisory board, speakers bureau, grant to institution), Roche (advisory board, grant to institution), Regeneron (advisory board), Amgen (honoraria), Novartis (advisory board), Eisai (advisory board), Protalix Biotherapeutics (advisory board, grant to institution), and CLS Therapeutics (grant to institution). Dr Werner reports the following disclosure: BMS (advisory board). All other authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling manuscripts for which they may have a conflict of interest. The editors and reviewers f this article have no conflicts of interest. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
